219 related articles for article (PubMed ID: 32886901)
1. Cost-Effectiveness of Initial Versus Delayed Lanreotide for Treatment of Metastatic Enteropancreatic Neuroendocrine Tumors.
Barnes JI; Lin JK; Gupta D; Owens DK; Goldhaber-Fiebert JD; Kunz PL
J Natl Compr Canc Netw; 2020 Sep; 18(9):1200-1209. PubMed ID: 32886901
[TBL] [Abstract][Full Text] [Related]
2. Everolimus, lutetium-177 DOTATATE and sunitinib for advanced, unresectable or metastatic neuroendocrine tumours with disease progression: a systematic review and cost-effectiveness analysis.
Mujica-Mota R; Varley-Campbell J; Tikhonova I; Cooper C; Griffin E; Haasova M; Peters J; Lucherini S; Talens-Bou J; Long L; Sherriff D; Napier M; Ramage J; Hoyle M
Health Technol Assess; 2018 Sep; 22(49):1-326. PubMed ID: 30209002
[TBL] [Abstract][Full Text] [Related]
3. Effect of Lanreotide Depot/Autogel on Urinary 5-Hydroxyindoleacetic Acid and Plasma Chromogranin A Biomarkers in Nonfunctional Metastatic Enteropancreatic Neuroendocrine Tumors.
Pavel ME; Phan AT; Wolin EM; Mirakhur B; Liyanage N; Pitman Lowenthal S; Fisher GA; Vinik AI;
Oncologist; 2019 Apr; 24(4):463-474. PubMed ID: 30355775
[TBL] [Abstract][Full Text] [Related]
4. [Antiproliferative Effect of Somatostatin Analogs - Data Analyses and Clinical Applications in the Context of the CLARINET Study].
Bencsiková B
Klin Onkol; 2016; 29(4):253-8. PubMed ID: 27534781
[TBL] [Abstract][Full Text] [Related]
5. Lanreotide in metastatic enteropancreatic neuroendocrine tumors.
Caplin ME; Pavel M; Ćwikła JB; Phan AT; Raderer M; Sedláčková E; Cadiot G; Wolin EM; Capdevila J; Wall L; Rindi G; Langley A; Martinez S; Blumberg J; Ruszniewski P;
N Engl J Med; 2014 Jul; 371(3):224-33. PubMed ID: 25014687
[TBL] [Abstract][Full Text] [Related]
6. Anti-tumour effects of lanreotide for pancreatic and intestinal neuroendocrine tumours: the CLARINET open-label extension study.
Caplin ME; Pavel M; Ćwikła JB; Phan AT; Raderer M; Sedláčková E; Cadiot G; Wolin EM; Capdevila J; Wall L; Rindi G; Langley A; Martinez S; Gomez-Panzani E; Ruszniewski P;
Endocr Relat Cancer; 2016 Mar; 23(3):191-9. PubMed ID: 26743120
[TBL] [Abstract][Full Text] [Related]
7. Comparing the Cost of Treatment with Octreotide Long-Acting Release versus Lanreotide in Patients with Metastatic Gastrointestinal Neuroendocrine Tumors.
Ayyagari R; Neary M; Li S; Rokito A; Yang H; Xie J; Benson AB
Am Health Drug Benefits; 2017 Nov; 10(8):408-415. PubMed ID: 29263774
[TBL] [Abstract][Full Text] [Related]
8. Lutetium oxodotreotide (
Smith-Palmer J; Leeuwenkamp OR; Virk J; Reed N
BMC Cancer; 2021 Jan; 21(1):10. PubMed ID: 33402120
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of Lutetium [
Leeuwenkamp O; Smith-Palmer J; Ortiz R; Werner A; Valentine W; Blachier M; Walter T
J Med Econ; 2020 Dec; 23(12):1534-1541. PubMed ID: 32990484
[TBL] [Abstract][Full Text] [Related]
10. The Antiproliferative Role of Lanreotide in Controlling Growth of Neuroendocrine Tumors: A Systematic Review.
Michael M; Garcia-Carbonero R; Weber MM; Lombard-Bohas C; Toumpanakis C; Hicks RJ
Oncologist; 2017 Mar; 22(3):272-285. PubMed ID: 28220021
[TBL] [Abstract][Full Text] [Related]
11. Lanreotide vs octreotide LAR for patients with advanced gastroenteropancreatic neuroendocrine tumors: An observational time and motion analysis.
Ryan P; McBride A; Ray D; Pulgar S; Ramirez RA; Elquza E; Favaro JP; Dranitsaris G
J Oncol Pharm Pract; 2019 Sep; 25(6):1425-1433. PubMed ID: 30924737
[TBL] [Abstract][Full Text] [Related]
12. Topotecan, pegylated liposomal doxorubicin hydrochloride and paclitaxel for second-line or subsequent treatment of advanced ovarian cancer: a systematic review and economic evaluation.
Main C; Bojke L; Griffin S; Norman G; Barbieri M; Mather L; Stark D; Palmer S; Riemsma R
Health Technol Assess; 2006 Mar; 10(9):1-132. iii-iv. PubMed ID: 16545208
[TBL] [Abstract][Full Text] [Related]
13. Somatostatin Analogues in the Treatment of Neuroendocrine Tumors: Past, Present and Future.
Stueven AK; Kayser A; Wetz C; Amthauer H; Wree A; Tacke F; Wiedenmann B; Roderburg C; Jann H
Int J Mol Sci; 2019 Jun; 20(12):. PubMed ID: 31234481
[TBL] [Abstract][Full Text] [Related]
14. Lanreotide autogel/depot in advanced enteropancreatic neuroendocrine tumours: final results of the CLARINET open-label extension study.
Caplin ME; Pavel M; Phan AT; Ćwikła JB; Sedláčková E; Thanh XT; Wolin EM; Ruszniewski P;
Endocrine; 2021 Feb; 71(2):502-513. PubMed ID: 33052555
[TBL] [Abstract][Full Text] [Related]
15. Octreotide and Lanreotide in Gastroenteropancreatic Neuroendocrine Tumors.
Pokuri VK; Fong MK; Iyer R
Curr Oncol Rep; 2016 Jan; 18(1):7. PubMed ID: 26743514
[TBL] [Abstract][Full Text] [Related]
16. Initiation of Somatostatin analogues for neuroendocrine tumor patients: a cost-effectiveness analysis.
Rustgi SD; Oh A; Yang JY; Kang D; Wolin E; Kong CY; Hur C; Kim MK
BMC Cancer; 2021 May; 21(1):597. PubMed ID: 34030646
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of lanreotide in Korean patients with metastatic, well-differentiated gastroenteropancreatic-neuroendocrine tumors: a retrospective analysis.
Kang J; Yoo C; Hwang HS; Hong SM; Kim KP; Kim SY; Hong YS; Kim TW; Ryoo BY
Invest New Drugs; 2019 Aug; 37(4):763-770. PubMed ID: 30536151
[TBL] [Abstract][Full Text] [Related]
18. Octreotide acetate long-acting release in patients with metastatic neuroendocrine tumors pretreated with lanreotide.
Ricci S; Antonuzzo A; Galli L; Ferdeghini M; Bodei L; Orlandini C; Conte PF
Ann Oncol; 2000 Sep; 11(9):1127-30. PubMed ID: 11061606
[TBL] [Abstract][Full Text] [Related]
19. Cost-Effectiveness and Net Monetary Benefit of Olaparib Maintenance Therapy Versus No Maintenance Therapy After First-line Platinum-based Chemotherapy in Newly Diagnosed Advanced BRCA1/2-mutated Ovarian Cancer in the Italian National Health Service.
Armeni P; Borsoi L; Fornaro G; Jommi C; Colombo N; Costa F
Clin Ther; 2020 Jul; 42(7):1192-1209.e12. PubMed ID: 32591103
[TBL] [Abstract][Full Text] [Related]
20. Phase II study of lanreotide autogel in Japanese patients with unresectable or metastatic well-differentiated neuroendocrine tumors.
Ito T; Honma Y; Hijioka S; Kudo A; Fukutomi A; Nozaki A; Kimura Y; Motoi F; Isayama H; Komoto I; Hisamatsu S; Nakajima A; Shimatsu A
Invest New Drugs; 2017 Aug; 35(4):499-508. PubMed ID: 28470558
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
